We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$20.5M
(-9.7%)
Cap. Flow
-$12.4M
Cap. Flow
% of AUM
-6.5%
Top 10 Holdings %
Top 10 Hldgs %
8%
Holding
450
New
8
Increased
100
Reduced
215
Closed
125
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brookfield Infrastructure
BIPC
|
+$1.03M |
| 2 |
OXLC
Oxford Lane Capital
OXLC
|
+$1,000K |
| 3 |
ECC
Eagle Point Credit Company
ECC
|
+$951K |
| 4 |
ORAN
Orange
ORAN
|
+$441K |
| 5 |
SNP
CHINA PETROLEUM & CHEMICAL CORPORATION ADS (REP 100 ORDINARY H SHARES)
SNP
|
+$424K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$2.13M |
| 2 |
Western Midstream Partners
WES
|
+$888K |
| 3 |
CNXM
CNX Midstream Partners LP
CNXM
|
+$744K |
| 4 |
OSB
Norbord Inc.
OSB
|
+$695K |
| 5 |
Marathon Petroleum
MPC
|
+$594K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.34% |
| 2 | Real Estate | 18.02% |
| 3 | Energy | 12.43% |
| 4 | Materials | 10.7% |
| 5 | Financials | 6.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
176
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $376K | 0.2% |
5,034
-673
| -12% | -$44.9K |
|
177
Protagonist Therapeutics
PTGX
$8.8B
| $372K | 0.2% |
19,048
-2,591
| -12% | -$48.6K |
|
|
ALLK
178
DELISTED
Allakos
ALLK
| $371K | 0.19% |
4,551
-608
| -12% | -$49.4K |
|
179
Gladstone Investment Corp
GAIN
$655M
| $371K | 0.19% |
40,784
+4,994
| +14% | +$47.6K |
|
|
BSL
180
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$168M
| $369K | 0.19% |
26,830
-8,346
| -24% | -$111K |
|
181
Brookfield Renewable
BEPC
$5.93B
| $368K | 0.19% |
+9,432
| New | +$316K |
|
|
IGMS
182
DELISTED
IGM Biosciences
IGMS
| $364K | 0.19% |
4,933
-659
| -12% | -$39K |
|
183
Compugen
CGEN
$214M
| $360K | 0.19% |
22,149
-3,027
| -12% | -$49.6K |
|
184
SLR Investment Corp
SLRC
$708M
| $355K | 0.19% |
22,374
-4,764
| -18% | -$78.1K |
|
185
Arcutis Biotherapeutics
ARQT
$3.55B
| $354K | 0.19% |
12,081
-1,637
| -12% | -$43.7K |
|
|
AGEN
186
Agenus
AGEN
$275M
| $353K | 0.19% |
4,500
-613
| -12% | -$47.7K |
|
187
Moderna
MRNA
$22.1B
| $352K | 0.18% |
4,974
-686
| -12% | -$47.8K |
|
188
Iovance Biotherapeutics
IOVA
$2.1B
| $344K | 0.18% |
10,450
-1,419
| -12% | -$43.5K |
|
|
JRO
189
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
| $344K | 0.18% |
41,957
-13,103
| -24% | -$106K |
|
190
Ascendis Pharma A/S
ASND
$16.7B
| $342K | 0.18% |
2,215
-296
| -12% | -$42.5K |
|
191
Madrigal Pharmaceuticals
MDGL
$12.4B
| $342K | 0.18% |
2,879
-408
| -12% | -$44.3K |
|
192
Quince Therapeutics
QNCX
$18.9M
| $342K | 0.18% |
34
-5
| -13% | -$45.5K |
|
|
SWTX
193
DELISTED
SpringWorks Therapeutics
SWTX
| $342K | 0.18% |
7,168
-981
| -12% | -$41.8K |
|
194
Theravance Biopharma
TBPH
$875M
| $342K | 0.18% |
23,148
+1,950
| +9% | +$36.5K |
|
|
NSL
195
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $341K | 0.18% |
70,640
-22,351
| -24% | -$108K |
|
|
EIDX
196
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $341K | 0.18% |
6,745
-924
| -12% | -$41.5K |
|
197
Nuveen Floating Rate Income Fund
JFR
$1.24B
| $340K | 0.18% |
40,925
-14,435
| -26% | -$118K |
|
198
Ovid Therapeutics
OVID
$440M
| $337K | 0.18% |
58,716
-8,001
| -12% | -$53.5K |
|
199
Main Street Capital
MAIN
$5.14B
| $336K | 0.18% |
11,375
-2,210
| -16% | -$67.7K |
|
200
Mirum Pharmaceuticals
MIRM
$6.84B
| $336K | 0.18% |
17,458
-2,377
| -12% | -$51K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q3 2020 Portfolio in Review
As of Q3 2020, Virtus ETF Advisers held 450 positions worth $191M, down 9.7% from $211M the previous quarter. Its ten largest holdings account for 8% of the portfolio.
Virtus ETF Advisers withdrew a net $12.4M in Q3 2020, closing 125 positions and reducing 215 holdings. Its most notable exit was CNX Midstream Partners LP, an estimated $744K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 34% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Oxford Lane Capital worth $1.03M.
- Virtus ETF Advisers's largest Q3 2020 buy was Oxford Lane Capital: 46,671 shares worth $1.03M.
- Virtus ETF Advisers added most to Brookfield Infrastructure in Q3 2020, an estimated $1.03M increase.
- Virtus ETF Advisers's biggest Q3 2020 reduction was Delek Logistics, cutting an estimated $2.13M.
- Virtus ETF Advisers fully exited CNX Midstream Partners LP in Q3 2020, selling an estimated $744K.
- Virtus ETF Advisers's ten largest holdings make up 8% of its $191M portfolio in Q3 2020.
- Virtus ETF Advisers opened 8 new positions and closed 125 in Q3 2020.
- Virtus ETF Advisers's portfolio value fell 9.7% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.